| |
|
|
|
|
Aastrom Biosciences, Inc.(ASTM)
|
|
|
|
|
|
|
|
|
| 123Jump Rating: |
|
Underwriters: |
SG Cowen
|
| |
|
|
J. P. Morgan & Co.
|
| Status: |
|
|
|
| |
| Address: |
24 Frank Lloyd Wright Drive
|
FiledDate: |
|
| |
P.O. Fox 376
|
|
|
| |
Ann Arbor,
|
Filed Price Range ($): |
|
| |
|
|
|
| Telephone: |
(313) 930 5555 |
Filed Offer Amount ($ Million): |
$0.00 |
| |
|
|
|
| Fax: |
|
Shares Offered (Millions): |
3,250,000 |
| |
|
|
|
| Websites: |
|
Shares Outstanding (Millions): |
13,235,734 |
| |
|
|
|
| Management: |
Robert J. Kunze, Chairman/Director
|
IPO Date: |
|
| |
R. Douglas Armstrong, Pres./CEO/Dir.
|
|
|
| |
Todd E. Simpson, VP/CFO
|
Final Offer Price ($): |
$0.00 |
| |
|
|
|
| Industry: |
|
Final Offer Size (Millions of Shares): |
0.00 |
| |
|
|
|
| Employees: |
65 |
Final Offer Amount ($ Million): |
$0.00 |
| |
|
|
|
| Competitors: |
Amgen, Inc.
|
S-1 Forms: |
|
| |
CellPro, Inc.
|
|
|
| |
Systemix, Inc.
|
|
|
| |
|
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
|
|
|
- Avoid 
- Value Gap 
- Short-Term Growth
- Long-Term Growth 
- Long-Term Value
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income Data |
| Year |
Revenues |
Costs |
Oper Income |
Taxes |
Net Income |
EPS |
| 1994
|
872 |
7192 |
-6320 |
0.00 |
-6140 |
0.00 |
| 1995
|
517 |
6447 |
-5930 |
0.00 |
-5717 |
0.00 |
| 1996
|
1609 |
12142 |
-10533 |
0.00 |
-9917 |
-.98 |
|
|
|
|
|
|
|
| |
|
| |
|
|
